Early observations and pilot data that first suggested a new direction
Oncology treatment was historically based on tissue of origin: lung cancer drugs for lung cancer, breast cancer drugs for breast cancer. The discovery that specific molecular alterations drove tumor biology regardless of histology began challenging this paradigm. The IPASS trial (2009) demonstrated that EGFR mutation status, not histology alone, predicted response to gefitinib in NSCLC, establishing biomarker-directed therapy in solid tumors. Crizotinib's dramatic responses in ALK-rearranged NSCLC further validated the molecular targeting approach. Next-generation sequencing (NGS) technology made broad genomic profiling feasible, enabling identification of actionable mutations across the entire cancer genome in a single test.
Landmark RCTs and pivotal trials that established the evidence base
The FDA's landmark 2017 approval of pembrolizumab for any MSI-H/dMMR solid tumor regardless of histology was a watershed moment, the first tumor-agnostic drug approval in oncology history. This was based on data across 15 tumor types showing durable response rates of approximately 40%. Shortly after, larotrectinib received tumor-agnostic approval for NTRK fusion-positive cancers based on remarkable response rates of 75% across 17 tumor types in the combined LOXO-TRK-14001, SCOUT, and NAVIGATE trials. Entrectinib followed with similar tumor-agnostic approval for NTRK fusions. These approvals validated the principle that molecular alterations, not tissue of origin, could define treatment across all cancer types.
Follow-up studies, subgroup analyses, and real-world validation
Circulating tumor DNA (ctDNA) emerged as a transformative tool for non-invasive molecular profiling, treatment response monitoring, and minimal residual disease detection. The NCI-MATCH (Molecular Analysis for Therapy Choice) trial was the largest precision oncology trial ever conducted, screening over 6,000 patients and assigning them to biomarker-matched therapy arms regardless of tumor type. While individual arm response rates varied (5-38%), the trial demonstrated feasibility of molecular screening at scale. Basket trials (one drug, one biomarker, multiple tumor types) and umbrella trials (one tumor type, multiple biomarker-drug arms) became standard clinical trial designs. RET inhibitors (selpercatinib, pralsetinib), BRAF+MEK inhibitors, and KRAS G12C inhibitors (sotorasib, adagrasib) expanded the druggable genome.
Integration into clinical practice guidelines and recommendations
NCCN, ESMO, and ASCO guidelines now recommend comprehensive genomic profiling (NGS panels) for all advanced solid tumors to identify actionable alterations. MSI/dMMR testing is recommended for all solid tumors (not just colorectal) given the tumor-agnostic pembrolizumab approval. NTRK fusion testing is recommended across all tumor types. ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) provides a framework for classifying the level of evidence behind molecular-target-drug combinations. Liquid biopsy (ctDNA) is incorporated as a complementary or alternative approach when tissue is unavailable.
ESMO Precision Medicine Guidelines
Comprehensive genomic profiling recommended for all advanced solid tumors. ESCAT framework classifies molecular targets by evidence level. MSI/dMMR and NTRK fusion testing recommended pan-cancer. ctDNA acceptable when tissue unavailable.
NCCN Guidelines: Non-Small Cell Lung Cancer
Broad molecular profiling (NGS) for all non-squamous NSCLC and non-smoking squamous NSCLC. Minimum biomarkers: EGFR, ALK, ROS1, BRAF, NTRK, MET, RET, KRAS G12C, ERBB2. MSI-H/dMMR testing recommended.
Now
Current standard of care and ongoing research directions
Precision oncology has moved from a research concept to routine clinical practice. Comprehensive genomic profiling is standard for advanced cancers, with over 20 FDA-approved biomarker-directed therapies including multiple tumor-agnostic approvals. ctDNA is increasingly used for treatment selection, response monitoring, and minimal residual disease detection guiding adjuvant therapy decisions (e.g., DYNAMIC trial in colon cancer). Key challenges include the low frequency of individually actionable alterations (only 10-15% of patients receive matched therapy), resistance mechanisms requiring sequential/combination approaches, the cost of broad molecular profiling and targeted drugs, and health equity in access to precision medicine. Emerging frontiers include AI-driven biomarker discovery, synthetic lethality screening at scale, and ctDNA-guided adaptive clinical trials.
Tumor-agnostic approval means a drug is approved based on a molecular biomarker regardless of the cancer's tissue of origin. For example, pembrolizumab is approved for any MSI-H/dMMR solid tumor whether it originates in the colon, uterus, stomach, or any other organ. This represents a fundamental shift from treating cancer by location to treating by molecular profile.
What percentage of cancer patients benefit from precision oncology approaches?+
Currently, approximately 10-15% of patients with advanced solid tumors have a clinically actionable molecular alteration with an available matched therapy. This varies widely by tumor type: NSCLC has actionable alterations in >50% of adenocarcinomas, while other tumor types may have <5%. The percentage is growing as new targets and drugs are developed.
How is circulating tumor DNA (ctDNA) used in clinical oncology?+
ctDNA has three main clinical applications: (1) molecular profiling for treatment selection when tissue biopsy is unavailable or insufficient, (2) monitoring treatment response and detecting resistance mutations earlier than imaging, and (3) minimal residual disease detection after surgery to guide adjuvant therapy decisions. The DYNAMIC trial showed ctDNA-guided adjuvant chemotherapy in colon cancer was non-inferior to standard approaches.
What is the ESCAT framework?+
The ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) classifies molecular targets by evidence level: Tier I (ready for routine clinical use, validated in clinical trials), Tier II (investigational targets with preliminary evidence), Tier III (clinical evidence in other tumor types), and Tier IV (preclinical evidence only). It helps clinicians interpret genomic profiling results and prioritize treatment decisions.
